Cyclophosphamide - Revision history

Fletc151: /* References */

2019-06-08T18:49:25Z

References

← Older revision		Revision as of 18:49, 8 June 2019
Line 52:		Line 52:

	==References==		==References==
			*Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010;46(18):3158-3168. [PubMed 20932740]
			*Anderson JE, Appelbaum FR, Schoch G, et al, “Allogeneic Marrow Transplantation for Myelodysplastic Syndrome With Advanced Disease Morphology: A Phase II Study of Busulfan, Cyclophosphamide, and Total Body-Irradiation and Analysis of Prognostic Factors,” J Clin Oncol, 1996, 14(1):220-6. [PubMed 8558201]
			*Arndt C, Hawkins, D, Anderson JR, et al. Age is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin and Cyclophosphamide. J Clin Oncol. 2004;22(10):1894-1901. [PubMed 15143082]
			*Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009;27(31):5182-5188. doi: 10.1200/JCO.2009.22.3768. [PubMed 19770373]
			*Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 170.

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Mholtz: Text replacement - "OR" to "'''OR'''"

2017-05-31T03:22:40Z

Text replacement - "OR" to "'''OR'''"

← Older revision		Revision as of 03:22, 31 May 2017
Line 6:		Line 6:

	==Adult Dosing==		==Adult Dosing==
	*Vasculitis: 2 mg/kg PO daily OR 15mg/kg IV q2 weeks x3 then q3 weeks. Adjust dose to avoid severe leukopenia		*Vasculitis: 2 mg/kg PO daily '''OR''' 15mg/kg IV q2 weeks x3 then q3 weeks. Adjust dose to avoid severe leukopenia
	*Lupus nephritis: 1g/m(2) IV monthly		*Lupus nephritis: 1g/m(2) IV monthly
	*Neuropsychiatric lupus: 0.75 g/m(2) IV q1mo x 1 year, then q3mo x 3 years		*Neuropsychiatric lupus: 0.75 g/m(2) IV q1mo x 1 year, then q3mo x 3 years

ClaireLewis: Created page with "==Administration== Type: Antineoplastic/immune modulating agent Dosage Forms: Routes of Administration: IV, oral Common Trade Names: ==Adult Dosing== *Vasculitis: 2 mg/k..."

2016-11-13T04:37:56Z

Created page with "==Administration== *Type: Antineoplastic/immune modulating agent *Dosage Forms: *Routes of Administration: IV, oral *Common Trade Names: ==Adult Dosing== *Vasculitis: 2 mg/k..."

New page

==Administration==
*Type: Antineoplastic/immune modulating agent
*Dosage Forms:
*Routes of Administration: IV, oral
*Common Trade Names:

==Adult Dosing==
*Vasculitis: 2 mg/kg PO daily OR 15mg/kg IV q2 weeks x3 then q3 weeks. Adjust dose to avoid severe leukopenia
*Lupus nephritis: 1g/m(2) IV monthly
*Neuropsychiatric lupus: 0.75 g/m(2) IV q1mo x 1 year, then q3mo x 3 years
*Oncologic uses: Typically much higher doses (e.g. 40 to 50 mg/kg IV over several days)

==Pediatric Dosing==

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: D
*[[Lactation risk categories|Lactation risk]]: Infant risk has been demonstrated
*Renal dosing:
*Hepatic dosing:

==Contraindications==
*Allergy to class/drug
*Urinary outflow obstruction

==Adverse Reactions==
===Serious===
*Malignancy: leukemia, bladder, renal pelvis, dermis, angiosarcoma
*Pericardial effusion, cardiac tamponade
*Cardiac toxicity, CHF
*SJS/TEN
*Interstitial pneumonia, pulmonary fibrosis
*Infection/sepsis
*Bladder fibrosis/contracture, hemorrhagic cystitis,
*Azoospermia
===Common===
*Alopecia, skin pigmentation changes, rash, nail damage
*Nausea/vomiting, diarrhea, anorexia
*Leukopenia, neutropenia
*Amenorrhea

==Pharmacology==
*Half-life: 3-12h
*Metabolism: Hepatic
*Excretion: Renal

==Mechanism of Action==
*Alkylating agent, cross-links strands of DNA and RNA, inhibits protein synthesis

==Comments==

==See Also==

==References==
<references/>
[[Category:Pharmacology]]

Cyclophosphamide - Revision history

Fletc151: /* References */

Mholtz: Text replacement - "OR" to "'''OR'''"

ClaireLewis: Created page with "==Administration== *Type: Antineoplastic/immune modulating agent *Dosage Forms: *Routes of Administration: IV, oral *Common Trade Names: ==Adult Dosing== *Vasculitis: 2 mg/k..."

ClaireLewis: Created page with "==Administration== Type: Antineoplastic/immune modulating agent Dosage Forms: Routes of Administration: IV, oral Common Trade Names: ==Adult Dosing== *Vasculitis: 2 mg/k..."